Hagop M. Kantarjian
University of Texas MD Anderson Cancer Center
4152 Papers
32.7K Citations
Hagop M. Kantarjian is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Myeloid leukemia. The author has an hindex of 204, co-authored 3708 publications. Previous affiliations of Hagop M. Kantarjian include Rice University & University of Chicago.
Chat about Author
Papers
Preliminary Results of Treatment with Filgrastim for Relapse of Leukemia and Myelodysplasia after Allogeneic Bone Marrow Transplantation
Sergio Giralt,Susan Escudier,Hagop M. Kantarjian,Albert B. Deisseroth,Emil J. Freireich,Borje S. Andersson,Susan O'Brien,Michael Andreeff,Harold Fisher,Ann Cork,Cheryl F Hirsch-Ginsberg,Jose M. Trujillo,Sanford A. Stass,Richard E. Champlin +13 more
TL;DR: Filgrastim may be effective in selected cases of leukemic relapse after allogeneic bone marrow transplantation, and three of the seven patients had a complete hematologic and cytogenetic remission, with reestablishment of hematopoiesis of donor origin.
106
Chromosomal Abnormalities and Prognosis in NPM1-Mutated Acute Myeloid Leukemia : A Pooled Analysis of Individual Patient Data From Nine International Cohorts
Linus Angenendt,Christoph Röllig,Pau Montesinos,David Martínez-Cuadrón,Eva Barragán,Raimundo García,Carmen Botella,Pilar Rodríguez Martínez,Farhad Ravandi,Tapan M. Kadia,Hagop M. Kantarjian,Jorge E. Cortes,Gunnar Juliusson,Vladimir Lazarevic,Martin Höglund,Sören Lehmann,Christian Recher,Arnaud Pigneux,Sarah Bertoli,Pierre-Yves Dumas,Hervé Dombret,Claude Preudhomme,Jean Baptiste Micol,Christine Terré,Zdeněk Ráčil,Jan Novák,Pavel Žák,Andrew H. Wei,Ing Soo Tiong,Meaghan Wall,Elihu H. Estey,Carole Shaw,Rita Exeler,Lisa Wagenführ,Friedrich Stölzel,Christian Thiede,Matthias Stelljes,Georg Lenz,Jan Henrik Mikesch,Hubert Serve,Gerhard Ehninger,Wolfgang E. Berdel,Michael Kramer,Utz Krug,Christoph Schliemann +44 more
TL;DR: Karyotype abnormalities are significantly associated with outcome in N PM1mut/FLT3-ITDneg/low AML and cytogenetic risk predominates over molecular risk in NPM1 mutational status and should be classified and treated accordingly.
106
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
Naval Daver,Paolo Strati,Elias Jabbour,Tapan M. Kadia,Raja Luthra,Sa Wang,Keyur P. Patel,Farhad Ravandi,Jorge E. Cortes,Xiao Qin Dong,Hagop M. Kantarjian,Guillermo Garcia-Manero +11 more
TL;DR: FMS‐like tyrosine kinase III (FLT3) mutations occur in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) at a lower frequency than AML and does not predict poor outcome.
105
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Carlo Gambacorti-Passerini,Jorge E. Cortes,Jeffrey H. Lipton,Anna Dmoszynska,Raymond S.M. Wong,Victor Rossiev,Dmitri Pavlov,Karin Gogat Marchant,Ladan Duvillie,Navin Khattry,Hagop M. Kantarjian,Tim H. Brümmendorf +11 more
TL;DR: Bosutinib had a manageable safety profile distinct from that of imatinib in patients with newly diagnosed CP CML and events were managed in most patients with dose modification and/or concomitant medication.
105
Clinical features of de Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
Sanam Loghavi,Zhuang Zuo,Farhad Ravandi,Hagop M. Kantarjian,Carlos E. Bueso-Ramos,Liping Zhang,Rajesh R. Singh,Keyur P. Patel,L. Jeffrey Medeiros,Francesco C. Stingo,Mark J. Routbort,Jorge E. Cortes,Rajyalakshmi Luthra,Joseph D. Khoury +13 more
TL;DR: DNMT3A has a significant dominant effect on the clinical features and outcomes of de novo AML patients with concurrent DN MT3A, FLT3 and NPM1 mutations.